The role of selective estrogen receptor modulators in the treatment of Schizophrenia

Psychiatria Danubina

Volumn 28, Issue , 2016, Pages 45-48

  Bratek, Agnieszka ^a   Krysta, Krzysztof ^a   Drzyzga, Karolina ^a   Barańska, Justyna ^a   Kucia, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Estradiol; Raloxifene; Schizophrenia; Selective estrogen receptor modulators; SERM

Indexed keywords

ESTRADIOL; ESTROGEN; PLACEBO; PROGESTERONE; PROLACTIN; RALOXIFENE; RISPERIDONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

AUGMENTATION TREATMENT; CANCER RISK; CHEMOTHERAPY; COGNITION; CONFERENCE PAPER; DISEASE SEVERITY; ENDOMETRIUM CANCER; HUMAN; LEARNING; LONG TERM MEMORY; MENTAL PATIENT; NEGATIVE SYNDROME; NEUROPROTECTION; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SEX DIFFERENCE; SIGNAL TRANSDUCTION; SYMPTOM; VENOUS THROMBOEMBOLISM;

EID: 84989875880     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (28)

1. Begemann MJ, Dekker CF, van Lunenburg M, Sommer IE: Estrogen augmentation in schizophrenia: a quantitative review of current evidence. Schizophr Res 2012; 141:179-84.
2. Beral V, Banks E, Reeves G: Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002; 360:942-4.
3. Bergemann N, Mundt C, Parzer P., Jannakos I, Nagl I, Salbach B et al.: Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics. Schizophrenia Research 2005; 73:357-366.
4. Brann DW, Dhandapani K, Wakade C., Mahesh VB, Khan MM: Neurotrophic and neuroprotective actions of estrogen: basic mechanisms and clinical implications. Steroids 2007; 72:381-405.
5. Bruce-Keller A.J., Keeling JL, Keller J.N., Huang FF, Camondola S, Mattson MP: Antiinflammatory effects of estrogen on microglial activation. Endocrinology 2000; 141:3646-56.
6. Cohen RZ, Seeman MV, Gotowiec A, Kopala L: Earlier puberty as a predictor of later onset of schizophrenia in women. Am J Psychiatry 1999; 156:1059-64.
7. DeMichele A, Troxel AB, Berlin J.A., Weber AL, Bunin GR, Turzo E et al.: Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study. J Clin Oncol 2008; 26:4151-9.
8. Feigenson KA, Kusnecov AW, Silverstein SM: Inflammation and the two-hit hypothesis of schizophrenia. Neurosci Biobehav Rev 2014; 38:72-93.
9. Freedman R: Schizophrenia. N Engl J Med 2003; 349:1738-49.
10. Heringa SM, Begemann MJ, Goverde A.J., Sommer IE: Sex hormones and oxytocin augmentation strategies in schizophrenia: A quantitative review. Schizophr Res 2015; 168:603-13.
11. Huber TJ, Rollnik J, Wilhelms J., von zur Mühlen A, Emrich HM, Schneider U: Estradiol levels in psychotic disorders. Psychoneuroendocrinology 2001; 26:27-35.
12. Huerta-Ramos E., Iniesta R, Ochoa S., Cobo J, Miquel E, Roca M et al.: Effects of raloxifene on cognition in post-menopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. Eur Neuropsycho-pharmacol 2014; 24:223-31.
13. Khodaie-Ardakani M.R., Khosravi M, Zarinfard R., Nejati S, Mohsenian A, Tabrizi M et al.: A Placebo-Controlled Study of Raloxifene Added to Risperidone in Men with Chronic Schizophrenia. Acta Med Iran 2015; 53:337-45.
14. Kianimehr G, Fatehi F, Hashempoor S., Khodaei-Ardakani MR, Rezaei F, Nazari A et al.: Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial. Daru 2014; 22:55.
15. Kulkarni J, de Castella A, Fitzgerald PB, Gurvich C.T., Bailey M., Bartholomeusz C et al.: Estrogen in severe mental illness: a potential new treatment approach. Arch Gen Psychiatry 2008; 65:955-60.
16. Kulkarni J, Gurvich C, Lee S.J., Gilbert H., Gavrilidis E, de Castella A et al.: Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology 2010; 35:1142-7.
17. Kulkarni J, Gavrilidis E, Wang W., Worsley R, Fitzgerald PB, Gurvich C et al.: Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age. Mol Psychiatry 2015; 20:695-702.
18. Lindamer LA, Bailey A, Hawthorne W., Folsom DP, Gilmer TP, Garcia P et al.: Gender differences in characteristics and service use of public mental health patients with schizophrenia. Psychiatr Serv 2003; 54:1407-9.
19. Munk-Olsen T., Laursen TM, Pedersen C.B., Mors O., Mortensen PB: New parents and mental disorders: a population-based register study. JAMA 2006; 296:2582-9.
20. Munk-Olsen T., Laursen TM, Mendelson T, Pedersen C.B., Mors O., Mortensen PB: Risks and predictors of readmission for a mental disorder during the postpartum period. Arch Gen Psychiatry 2009; 66:189-95.
21. Riecher-Rössler A, Häfner H: Gender aspects in schizophrenia: bridging the border between social and biological psychiatry. Acta Psychiatr Scand 2000; Suppl 102:58-62.
22. Seeman MV, Lang M: The role of estrogens in schizophrenia gender differences. Schizophr Bull 1990; 16:185-94.
23. Slotema CW, Aleman A, Daskalakis Z.J., Sommer IE: Meta-analysis of repetitive transcranial magnetic stimulation in the treatment of auditory verbal hallucinations: update and effects after one month. Schizophr Res 2012; 142:40-5.
24. Tenenbaum M, Azab AN, Kaplanski J: Effects of estrogen against LPS-induced inflammation and toxicity in primary rat glial and neuronal cultures. Journal of Endotoxin Research 2007; 13:158-166.
25. Usall J, Huerta-Ramos E, Iniesta R., Cobo J, Araya S, Roca M et al.: Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a doubleblind, randomized, placebo-controlled trial. J Clin Psychiatry 2011; 72:1552-7.
26. Usall J, Huerta-Ramos E, Labad J., Cobo J, Núñez C, Creus M et al.: Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia: A 24-Week Double-Blind, Randomized, Parallel, Placebo-Controlled Trial. Schizophr Bull 2016; 42:309-17.
27. Weickert TW, Weinberg D, Lenroot R., Catts SV, Wells R, Vercammen A et al.: Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia. Mol Psychiatry 2015; 20:685-94.
28. Wieck A: Oestradiol and psychosis: clinical findings and biological mechanisms. Curr Top Behav Neurosci 2011; 8:173-87.